Business
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial, the company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year Dr Dana Hilt, CMO, commented:“There remains an enormo
About this update from Actinogen Medical Limited
[{"type":"image","alt":"Actinogen Medical","displaySize":"","headline":null,"caption":"Actinogen Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TQImuMTxtef96v4yTMESFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4","width":300,"height":300}},"lazy":false},{"type":"text","content":"On track for interim analysis in late January 2026 and topline final results November 2026","length":90,"tagName":"p"},{"type":"text","content":"SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial, the company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year","length":356,"tagName":"p"},{"type":"text","content":"Dr Dana Hilt, CMO, commented:“There remains an enormous unmet medical need for patients at all stages of Alzheimer’s despite the recent availability of new monoclonal antibody therapies. Oral Xanamem has the potential to be a game-changer for Alzheimer’s patients because of its safety, ease-of-use and potential efficacy advantages. We are very grateful to trial staff, patients and their caregivers for their enthusiastic partnership in the Xanamem program.”","length":461,"tagName":"p"},{"type":"text","content":"Key points:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"XanaMIA is a randomized trial of 36 weeks treatment with Xanamem® or placebo in patients with mild-moderate Alzheimer’s disease followed by an open-label extension phase","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Final and total enrolment is 247 participants (originally targeted 220)","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline final results are confirmed for November of next year (previously mid Q4) with full analysis to be completed in the months following","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"A webinar to discuss this announcement and related information was held during Sydney business h...